Table 4.

ORs and 95% CIs for ovarian germ cell tumors (GCT) associated with doubling of hormone concentrations from the Finnish Maternity Cohort, 1983–2007^*

	testosterone		androstenedione		17-OH-progesterone		progesterone		estradiol
	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
GCT (21/58)	1.05 (0.54–2.08)	0.88	1.19 (0.54–2.65)	0.66	0.67 (0.27–1.67)	0.39	1.13 (0.42–2.99)	0.81	0.75 (0.42–1.36)	0.35
Multivariate model (21/58)	1.04 (0.50–2.17)	0.92	1.24 (0.53–2.91)	0.62	0.66 (0.26–1.66)	0.37	1.04 (0.38–2.84)	0.94	0.68 (0.35–1.33)	0.26
Sensitivity analyses
Lag time ≥ 2 years (16/45)	0.82 (0.34–1.96)	0.66	1.05 (0.37–2.94)	0.93	0.59 (0.21–1.67)	0.32	1.08 (0.27–4.24)	0.91	0.73 (0.31–1.74)	0.48
Lag time ≥ 4 years (11/31)	0.60 (0.15–2.44)	0.47	0.66 (0.13–3.29)	0.62	0.45 (0.09–2.17)	0.32	0.86 (0.10–7.32)	0.89	0.59 (0.15–2.30)	0.45
Lag time ≥ 6 years (9/26)	0.56 (0.13–2.36)	0.43	0.59 (0.11–3.06)	0.53	0.36 (0.06–2.09)	0.25	0.89 (0.11–7.56)	0.92	0.57 (0.13–2.52)	0.42
Multiparous women (15/42)	0.94 (0.41–2.15)	0.88	1.23 (0.47–3.22)	0.67	0.69 (0.21–2.23)	0.53	1.71 (0.36–8.20)	0.50	0.61(0.25–1.51)	0.29
Invasive tumors (18/50)	1.07 (0.49–2.35)	0.87	1.21 (0.50–2.93)	0.68	0.77 (0.30–2.01)	0.59	1.00 (0.34–2.92)	0.99	0.65 (0.32–1.32)	0.23

^*None of the heterogeneity tests reached statistical significance and adjustment for gestational age, maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, and child sex.